从血管紧张素转化酶 2 寻找新型冠状病毒肺炎的治疗策略：COVID-19 和 SARS-CoV 的靶点。
Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
机构信息
Hebei General Hospital, Shijiazhuang, 050051, Hebei, China.
Hebei General Hospital, Graduate School of Hebei Medical University, Shijiazhuang, 050000, China.
出版信息
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1021-1026. doi: 10.1007/s10096-020-03883-y. Epub 2020 Apr 13.
Abstract
Since December 2019, the infection of the new coronavirus (COVID-19) caused an outbreak of new coronavirus pneumonia in Wuhan, China, and caused great public concern. Both COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through ACE2. An in-depth understanding of ACE2 and a series of physiological and physiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical phenomena and then deal with them timely. In addition, ACE2 is a potential therapeutic target. This article will summarize the role of ACE2 in multiple organ damage caused by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit inflammation in order to provide the basis for subsequent related research, diagnosis and treatment, and drug development.
摘要
自 2019 年 12 月以来，新型冠状病毒（COVID-19）的感染在中国武汉引发了新型冠状病毒肺炎疫情，引起了公众的极大关注。COVID-19 和 SARS-CoV 都属于冠状病毒家族，均通过 ACE2 入侵靶细胞。深入了解 ACE2 以及病毒入侵人体引起的一系列生理和病理变化，可能有助于发现并解释相应的临床现象，进而及时处理。此外，ACE2 是一个有潜力的治疗靶点。本文将总结 ACE2 在 COVID-19 和 SARS-CoV 引起的多器官损伤中的作用、针对 ACE2 的靶向阻断药物以及抑制炎症的药物，以期为后续相关研究、诊断和治疗以及药物研发提供依据。
相似文献
1
Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.从血管紧张素转化酶 2 寻找新型冠状病毒肺炎的治疗策略：COVID-19 和 SARS-CoV 的靶点。
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1021-1026. doi: 10.1007/s10096-020-03883-y. Epub 2020 Apr 13.
2
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.血管紧张素转换酶 2 的器官保护作用及其对 COVID-19 预后的影响。
J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5.
3
Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).新型冠状病毒病 2019（COVID-19）与肾素-血管紧张素系统：深入了解血管紧张素转换酶 2（ACE2）。
Ann Clin Biochem. 2020 Sep;57(5):339-350. doi: 10.1177/0004563220928361. Epub 2020 Jun 2.
4
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).血管紧张素转化酶 2（ACE2）、严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）与 2019 冠状病毒病（COVID-19）的病理生理学。
J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10.
5
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.SARS-CoV-2 大流行和研究空白：了解 SARS-CoV-2 与 ACE2 受体的相互作用及其对治疗的影响。
Theranostics. 2020 Jun 12;10(16):7448-7464. doi: 10.7150/thno.48076. eCollection 2020.
6
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications.SARS-CoV-2 与其他冠状病毒与 ACE（血管紧张素转换酶）-2 作为其主要受体的相互作用：治疗意义。
Hypertension. 2020 Nov;76(5):1339-1349. doi: 10.1161/HYPERTENSIONAHA.120.15256. Epub 2020 Aug 27.
7
Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.天然类黄酮作为潜在的血管紧张素转换酶 2 抑制剂用于抗 SARS-CoV-2。
Molecules. 2020 Sep 1;25(17):3980. doi: 10.3390/molecules25173980.
8
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?可溶性血管紧张素转化酶 2：冠状病毒感染治疗的潜在方法？
Clin Sci (Lond). 2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163.
9
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).螺内酯可能提供针对 SARS-CoV-2 的保护：靶向雄激素、血管紧张素转换酶 2（ACE2）和肾素-血管紧张素-醛固酮系统（RAAS）。
Med Hypotheses. 2020 Oct;143:110112. doi: 10.1016/j.mehy.2020.110112. Epub 2020 Jul 16.
10
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.SARS-CoV-2 与心血管并发症：从分子机制到药物治疗管理。
Biochem Pharmacol. 2020 Aug;178:114114. doi: 10.1016/j.bcp.2020.114114. Epub 2020 Jun 21.
引用本文的文献
1
SARS-CoV-2: A synergy to the Alzheimer's disease.严重急性呼吸综合征冠状病毒2：与阿尔茨海默病的协同作用。
J Neurovirol. 2025 Feb;31(1):16-23. doi: 10.1007/s13365-025-01247-w. Epub 2025 Feb 25.
2
Hyperinflammatory Response in COVID-19: A Systematic Review.COVID-19 中的过度炎症反应：系统评价。
Viruses. 2023 Feb 16;15(2):553. doi: 10.3390/v15020553.
3
Elevated Natriuretic Peptides in Patients With Severe or Critical COVID-19: A Meta-Analysis.严重或危重新冠肺炎患者中利钠肽水平升高：一项荟萃分析。
Tex Heart Inst J. 2022 Sep 1;49(5). doi: 10.14503/THIJ-20-7404.
4
Lymphocyte count is a universal predictor of health outcomes in COVID-19 patients before mass vaccination: A meta-analytical study.淋巴细胞计数是大规模接种疫苗前 COVID-19 患者健康结局的通用预测因子：一项荟萃分析研究。
J Glob Health. 2022 Sep 17;12:05041. doi: 10.7189/jogh.12.05041.
5
Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated?与 SARS-CoV-2 感染相关的脑血管并发症：它是如何发生的，应该如何治疗？
Biomed Pharmacother. 2022 Oct;154:113534. doi: 10.1016/j.biopha.2022.113534. Epub 2022 Aug 17.
6
PATIENT CLINICAL CONDITION IN RELATION TO HYPOXEMIA AND CHEST X-RAY CHANGES IN NOVEL CoV-19 PNEUMONIA: A CASE REPORT.新型 CoV-19 肺炎患者低氧血症与胸部 X 线改变的临床状况：一例报告。
Acta Clin Croat. 2021 Dec;60(4):769-772. doi: 10.20471/acc.2021.60.04.26.
7
Critically Ill Pediatric Patient and SARS-CoV-2 Infection.危重症儿科患者与新型冠状病毒2型感染
Children (Basel). 2022 Apr 11;9(4):538. doi: 10.3390/children9040538.
8
Basic virology of SARS-CoV 2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的基础病毒学
Indian J Med Microbiol. 2022 Apr-Jun;40(2):182-186. doi: 10.1016/j.ijmmb.2022.02.005. Epub 2022 Mar 14.
9
"Anosmia" the mysterious collateral damage of COVID-19.新冠病毒的神秘附带损伤：嗅觉丧失。
J Neurovirol. 2022 Apr;28(2):189-200. doi: 10.1007/s13365-022-01060-9. Epub 2022 Mar 5.
10
Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity.COVID-19 的风险因素：糖尿病、高血压和肥胖。
Adv Exp Med Biol. 2021;1353:115-129. doi: 10.1007/978-3-030-85113-2_7.
本文引用的文献
1
Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.单细胞 RNA 测序数据分析受体 ACE2 的表达揭示了不同人体器官易感染 2019-nCoV 的潜在风险。
Front Med. 2020 Apr;14(2):185-192. doi: 10.1007/s11684-020-0754-0. Epub 2020 Mar 12.
2
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
3
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.新型冠状病毒在武汉持续爆发中的进化及其刺突蛋白对人类传播风险的建模。
Sci China Life Sci. 2020 Mar;63(3):457-460. doi: 10.1007/s11427-020-1637-5. Epub 2020 Jan 21.
4
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
5
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
6
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
7
Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia.血管紧张素转换酶抑制剂和他汀类药物对病毒性肺炎的影响。
Proc (Bayl Univ Med Cent). 2018 Oct 26;31(4):419-423. doi: 10.1080/08998280.2018.1499293. eCollection 2018 Oct.
8
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.一项重组人血管紧张素转换酶 2 在急性呼吸窘迫综合征中的临床试验。
Crit Care. 2017 Sep 7;21(1):234. doi: 10.1186/s13054-017-1823-x.
9
Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.肾素-血管紧张素-醛固酮抑制在心血管疾病治疗中的应用。
Pharmacol Res. 2017 Nov;125(Pt A):57-71. doi: 10.1016/j.phrs.2017.05.020. Epub 2017 May 29.
10
Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation.蛋白酶激活受体1促成血管紧张素II诱导的心血管重塑和炎症。
Cardiology. 2017;136(4):258-268. doi: 10.1159/000452269. Epub 2016 Nov 24.
Zotero 插件